NCT05561530View on ClinicalTrials.gov

A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 7, 2022

Primary Completion Date

June 15, 2023

Study Completion Date

June 15, 2023

Conditions
Chronic Hepatitis B
Interventions
DRUG

ALG-125755

single or multiple doses of ALG-125755

DRUG

Placebo

single or multiple doses of placebo

Trial Locations (4)

Unknown

MBAL Sveta Sofia EOOD, Dept of Internal Medicine with Gastroenterology Section, Sofia

"PMSI Republican Clinical Hospital t. Mosneaga, ARENSIA Exploratory Medicine Phase 1 Unit", Chisinau

New Zealand Clinical Research, Auckland

National Institute for Infection Diseases, ARENSIA Exploratory Medicine S.R.L., Bucharest

Sponsors
All Listed Sponsors
lead

Aligos Therapeutics

INDUSTRY

NCT05561530 - A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects | Biotech Hunter | Biotech Hunter